Overview

Loncastuximab Tesirine in WM

Status:
Not yet recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The name of the study drug involved in this study is: - Loncastuximab tesirine
Phase:
Phase 2
Details
Lead Sponsor:
Shayna Sarosiek, MD
Collaborator:
ADC Therapeutics
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate
Loncastuximab tesirine